Phase III Trial Compares Semaglutide Injection to Wegovy for Obesity

Obesity is a global health crisis linked to numerous comorbidities like type 2 diabetes and cardiovascular disease. While semaglutide, a GLP-1 receptor agonist, has shown significant efficacy in weight management, different formulations and manufacturers exist. This Phase III clinical trial directly addresses the knowledge gap regarding the comparative efficacy and safety of a novel semaglutide injection versus the established Wegovy® brand for weight loss in obese individuals.

As this study is currently NOT_YET_RECRUITING, no actual findings are available. However, the primary objective is to assess the comparative effect on body weight. Researchers will look for a significant mean percentage change in body weight from baseline in both groups. It is anticipated that both Semaglutide injection and Wegovy® will lead to substantial weight loss, potentially in the range of 15-20% over the 2-year period, based on previous semaglutide trials. The study's core aim is to determine if the novel Semaglutide injection achieves non-inferior or superior body weight reduction compared to Wegovy®, with an expected difference of at least 1-2% in mean body weight loss between the groups. Secondary outcomes will likely include changes in body mass index (BMI), waist circumference, and safety profiles, with an expected low incidence of severe adverse events, potentially less than 5%.